KPTI – karyopharm therapeutics inc. (US:NASDAQ)
Stock Stats
News
4/27
02:28 pm
kpti
Low
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $16.00 price target on the stock, up from $8.00.
4/21
10:32 am
kpti
Low
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
4/17
10:27 am
kpti
Low
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance [Yahoo! Finance]
3/30
02:17 pm
kpti
Low
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
3/26
07:02 am
kpti
Low
Karyopharm: Putting The Phase 3 Trial In Context [Seeking Alpha]
2/12/2026
07:30 am
KPTI
27.6%
MISS
11/3/2025
07:00 am
KPTI
1.3%
MISS
8/11/2025
07:30 am
KPTI
-5.8%
MISS
5/12/2025
04:05 pm
KPTI
-20.0%
BEAT
3/25
08:20 am
Maintains
Outperform
Outperform
Baird
Medium
-4.2%
3/25
08:20 am
Maintains
Outperform
Outperform
Baird
Medium
-4.2%
3/17
06:52 am
Upgrades
Strong-Buy
Rodman & Renshaw
Medium
-4.7%
3/17
06:52 am
Upgrades
Strong-Buy
Rodman & Renshaw
Medium
-4.7%
3/10
06:20 am
Initiates
Buy
Rodman & Renshaw
Medium
-3.1%
4/22
04:04 pm
kpti
Medium
Form 4 Karyopharm Therapeutics For: Apr 21 Filed by: Rangwala Reshma
4/13
05:29 pm
kpti
Medium
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC
4/13
08:25 am
kpti
Medium
Form ARS Karyopharm Therapeutics For: Dec 31
4/13
08:23 am
kpti
Medium
Form DEF 14A Karyopharm Therapeutics For: Apr 13
4/2
04:47 pm
kpti
Medium
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Show more
Top News Gainers
2/28 Form 3 Karyopharm Therapeutics For: Feb 26 Filed by: Paulson Richard A. 70.1%
9/16 Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million 10.7%
3/3 Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock 9.8%
5/15 Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award 8.6%
10/9 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%
1/8 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $21.00 price target on the stock. 7.2%
11/1 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 7.2%
4/20 Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 7.1%
11/4 Karyopharm Therapeutics Inc (KPTI) Q3 2019 Earnings Call Transcript [The Motley Fool] 6.9%
7/30 Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019 6.9%
Top News Decliners
3/13 Form S-8 Karyopharm Therapeutics -13.2%
3/12 Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer -13.1%
3/6 Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares -13.0%
7/5 Karyopharm Therapeutics Inc (NASDAQ: KPTI) had its price target raised by analysts at HC Wainwright from $29.00 to $32.00. They now have a "buy" rating on the stock. -11.5%
3/2 Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock -9.8%
1/17 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.5%
8/1 Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. -9.4%
3/5 Karyopharm Therapeutics: All Systems Go [Seeking Alpha] -9.0%
7/10 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. -8.4%
3/17 Form 3 Karyopharm Therapeutics For: Mar 16 Filed by: DEMAREE JOHN -8.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3